These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 35315916)

  • 1. Immune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults.
    Schonfeld SJ; Tucker MA; Engels EA; Dores GM; Sampson JN; Shiels MS; Chanock SJ; Morton LM
    JAMA Netw Open; 2022 Mar; 5(3):e223461. PubMed ID: 35315916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of Immune-related Adverse Events in Melanoma Patients With Preexisting Autoimmune Disease Treated With Immune Checkpoint Inhibitors: A Population-based Study Using SEER-Medicare Data.
    Tully KH; Cone EB; Cole AP; Sun M; Chen X; Marchese M; Roghmann F; Kilbridge KL; Trinh QD
    Am J Clin Oncol; 2021 Aug; 44(8):413-418. PubMed ID: 34081033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
    Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
    JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of the American Joint Committee on Cancer Eighth Edition Staging of Patients With Metastatic Cutaneous Melanoma Treated With Immune Checkpoint Inhibitors.
    Waninger JJ; Ma VT; Journey S; Skvarce J; Chopra Z; Tezel A; Bryant AK; Mayo C; Sun Y; Sankar K; Ramnath N; Lao C; Sussman JB; Fecher L; Alva A; Green MD
    JAMA Netw Open; 2021 Mar; 4(3):e210980. PubMed ID: 33687443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of age with survival in older patients with cutaneous melanoma treated with immune checkpoint inhibitors.
    Howell AV; Gebregziabher M; Thiers BH; Graboyes EM; Paulos CM; Wrangle JM; Hunt KJ; Wallace K
    J Geriatr Oncol; 2022 Sep; 13(7):1003-1010. PubMed ID: 35660090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitors retain effectiveness in older patients with cutaneous metastatic melanoma.
    Howell AV; Gebregziabher M; Thiers BH; Paulos CM; Wrangle JM; Hunt KJ; Wallace K
    J Geriatr Oncol; 2021 Apr; 12(3):394-401. PubMed ID: 33132048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry.
    Sun MM; Kelly SP; Mylavarapu Bs AL; Holland GN; Coleman AL; Yu F; Hsu Ms S; Lum F; Gordon LK
    Ophthalmology; 2021 Jun; 128(6):910-919. PubMed ID: 33166553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors.
    George S; Bell EJ; Zheng Y; Kim R; White J; Devgan G; Smith J; Lal LS; Engel-Nitz NM; Liu FX
    Oncologist; 2021 Jul; 26(7):e1205-e1215. PubMed ID: 33955118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma.
    Pepys J; Stoff R; Ramon-Gonen R; Ben-Betzalel G; Grynberg S; Frommer RS; Schachter J; Asher N; Taliansky A; Nikitin V; Dori A; Shelly S
    Neurology; 2023 Dec; 101(24):e2472-e2482. PubMed ID: 37652699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk Factors for the Development of Bullous Pemphigoid in US Patients Receiving Immune Checkpoint Inhibitors.
    Said JT; Liu M; Talia J; Singer SB; Semenov YR; Wei EX; Mostaghimi A; Nelson CA; Giobbie-Hurder A; LeBoeuf NR
    JAMA Dermatol; 2022 May; 158(5):552-557. PubMed ID: 35416925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint inhibitors-associated risk of immune-related hypothyroidism in older patients with advanced melanoma: a real-world analysis of US SEER-Medicare data.
    Almutairi AR; Erstad BL; McBride A; Slack M; Abraham I
    Expert Opin Drug Saf; 2021 Apr; 20(4):489-497. PubMed ID: 33445985
    [No Abstract]   [Full Text] [Related]  

  • 12. The association between toxicity and efficacy of immune checkpoint inhibitors in older adults with NSCLC.
    Rong Y; Ramachandran S; Bhattacharya K; Yang Y; Earl S; Chang Y; Bentley JP
    Immunotherapy; 2024; 16(16-17):1057-1068. PubMed ID: 39268919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
    Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
    JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States.
    Jain P; Gutierrez Bugarin J; Guha A; Jain C; Patil N; Shen T; Stanevich I; Nikore V; Margolin K; Ernstoff M; Velcheti V; Barnholtz-Sloan J; Dowlati A
    ESMO Open; 2021 Oct; 6(5):100252. PubMed ID: 34461483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.
    Mikami T; Liaw B; Asada M; Niimura T; Zamami Y; Green-LaRoche D; Pai L; Levy M; Jeyapalan S
    J Neurooncol; 2021 Mar; 152(1):135-144. PubMed ID: 33423151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with immune checkpoint inhibitor use among older adults with late-stage melanoma: A population-based study.
    Rai P; Shen C; Kolodney J; Kelly KM; Scott VG; Sambamoorthi U
    Medicine (Baltimore); 2021 Feb; 100(7):e24782. PubMed ID: 33607829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review.
    Chai QQ; Du JY; Zhu J; Wu B
    Front Pharmacol; 2019; 10():1260. PubMed ID: 31708783
    [No Abstract]   [Full Text] [Related]  

  • 18. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
    Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma.
    Akturk HK; Couts KL; Baschal EE; Karakus KE; Van Gulick RJ; Turner JA; Pyle L; Robinson WA; Michels AW
    JAMA Netw Open; 2022 Dec; 5(12):e2246400. PubMed ID: 36512357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Trends in Second Primary Cancers in Patients With Metastatic Melanoma From 2005 to 2016.
    Deng W; Wang Y; Liu X; Liu J; Wang L; Yang Z; Yang M; An Y; Tang C; Sanford NN; Kim BYS; Jiang W
    JAMA Netw Open; 2020 Dec; 3(12):e2028627. PubMed ID: 33295975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.